- Home
- ADPT vs CNCK Comparison
ADPT vs CNCK Comparison
Compare ADPT & CNCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- CNCK
- Stock Information
- Founded
- ADPT 2009
- CNCK 2012
- Country
- ADPT United States
- CNCK Netherlands
- Employees
- ADPT N/A
- CNCK N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- CNCK
- Sector
- ADPT Health Care
- CNCK
- Exchange
- ADPT Nasdaq
- CNCK NYSE
- Market Cap
- ADPT 1.1B
- CNCK N/A
- IPO Year
- ADPT 2019
- CNCK N/A
- Fundamental
- Price
- ADPT $7.43
- CNCK $4.95
- Analyst Decision
- ADPT Strong Buy
- CNCK Buy
- Analyst Count
- ADPT 5
- CNCK 1
- Target Price
- ADPT $9.40
- CNCK $10.00
- AVG Volume (30 Days)
- ADPT 2.2M
- CNCK 33.6K
- Earning Date
- ADPT 05-06-2025
- CNCK 05-16-2025
- Dividend Yield
- ADPT N/A
- CNCK N/A
- EPS Growth
- ADPT N/A
- CNCK N/A
- EPS
- ADPT N/A
- CNCK N/A
- Revenue
- ADPT $178,957,000.00
- CNCK $2,354,350,618.00
- Revenue This Year
- ADPT $21.21
- CNCK N/A
- Revenue Next Year
- ADPT $21.98
- CNCK N/A
- P/E Ratio
- ADPT N/A
- CNCK N/A
- Revenue Growth
- ADPT 5.10
- CNCK 57.02
- 52 Week Low
- ADPT $2.28
- CNCK $4.75
- 52 Week High
- ADPT $9.01
- CNCK $14.99
- Technical
- Relative Strength Index (RSI)
- ADPT 44.19
- CNCK N/A
- Support Level
- ADPT $6.92
- CNCK N/A
- Resistance Level
- ADPT $9.01
- CNCK N/A
- Average True Range (ATR)
- ADPT 0.57
- CNCK 0.00
- MACD
- ADPT -0.01
- CNCK 0.00
- Stochastic Oscillator
- ADPT 24.58
- CNCK 0.00
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).